WO2026010595 - A MODIFIED RELEASE TABLET COMPOSITION COMPRISING MIRABEGRON
National phase entry is expected:
Publication Number
WO/2026/010595
Publication Date
08.01.2026
International Application No.
PCT/TR2025/050684
International Filing Date
01.07.2025
Title **
[English]
A MODIFIED RELEASE TABLET COMPOSITION COMPRISING MIRABEGRON
[French]
COMPOSITION DE COMPRIMÉ À LIBÉRATION MODIFIÉE COMPRENANT DU MIRABEGRON
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
ATAK, Fadime Bilgehan
ATAMAN, Seval
KARABULUT, Serif
Priority Data
2024/008630
04.07.2024
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2102 | |
| EPO | Filing, Examination, Granting | 9177 | |
| Japan | Filing, Examination, Granting | 2161 | |
| South Korea | Filing, Examination, Granting | 2121 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
22,101
Contact Us
Abstract[English]
The present invention relates to a modified release tablet composition comprising mirabegron and polyethylene oxide wherein; mirabegron having a d (0.9) particle size less than 50 µm and polyethylene oxide having a molecular weight of between 4,000,000 and 7,000,000.[French]
La présente invention concerne une composition de comprimé à libération modifiée comprenant du mirabegron et de l'oxyde de polyéthylène, le mirabegron ayant une taille de particule d (0,9) inférieure à 50 µm et l'oxyde de polyéthylène ayant un poids moléculaire compris entre 4 000 000 et 7 000 000.